Cargando…

Current State of Clostridium difficile Treatment Options

Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venugopal, Anilrudh A., Johnson, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388023/ https://www.ncbi.nlm.nih.gov/pubmed/22752868 http://dx.doi.org/10.1093/cid/cis355

Ejemplares similares

Current Status of Clostridium difficile Infection Epidemiology
por: Lessa, Fernanda C., et al.
Publicado: (2012)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Burden of Clostridium difficile on the Healthcare System
por: Dubberke, Erik R., et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management
por: Eyre, David W., et al.
Publicado: (2012)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Surface-Layer Protein A (SlpA) Is a Major Contributor to Host-Cell Adherence of Clostridium difficile
por: Merrigan, Michelle M., et al.
Publicado: (2013)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis
por: Bauer, Martijn P., et al.
Publicado: (2012)

Navigating changes in Clostridioides difficile prevention and treatment
por: Durham, Spencer H, et al.
Publicado: (2020)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Current Treatment Options for Acute Skin and Skin-structure Infections
por: Golan, Yoav
Publicado: (2019)

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
por: Sears, Pamela, et al.
Publicado: (2012)

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

Therapeutic Options in the Prevention and Treatment of Postmenopausal Osteoporosis
por: Kamel, Hosam K., et al.
Publicado: (2006)

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017)

Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options
por: Goudarzi, Mehdi, et al.
Publicado: (2014)

Current advances related to Clostridium difficile infection
por: Kim, Yong Gil, et al.
Publicado: (2015)

The Challenging Conundrum of Diagnosing and Managing Clostridium difficile Infection
por: Gerding, Dale N., et al.
Publicado: (2017)

511. What Is the Current State of Patient Education after Clostridium difficile Infection?
por: DeBenedictus, Christina, et al.
Publicado: (2018)

Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes
por: Gleeson, Jeremy M., et al.
Publicado: (2005)

Clostridium difficile Infection, Colorado and the Northwestern United States, 2007
por: Kuntz, Jennifer L., et al.
Publicado: (2012)

Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
por: Rao, Vamshi K., et al.
Publicado: (2018)

Clostridium difficile colitis – a serious current problem
por: Dumitru, Irina Magdalena, et al.
Publicado: (2013)

Current knowledge on the laboratory diagnosis of Clostridium difficile infection
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2017)

Evaluation of the Xpert Clostridium difficile Assay for the Diagnosis of Clostridium difficile Infection
por: Shin, Saeam, et al.
Publicado: (2012)

Clostridium difficile infection
por: Geller, Stephen A., et al.
Publicado: (2014)

Clostridium difficile Infection
por: Magdesian, K. Gary
Publicado: (2003)

Toxin B is essential for virulence of Clostridium difficile
por: Lyras, Dena, et al.
Publicado: (2009)

Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014
por: Snydman, David R, et al.
Publicado: (2017)

Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives (†)
por: Hussack, Greg, et al.
Publicado: (2010)

Clostridium difficile infection: a review of current and emerging therapies
por: Ofosu, Andrew
Publicado: (2016)

Clostridium difficile–associated Disease in the Elderly, United States
por: Jagai, Jyotsna, et al.
Publicado: (2009)

Clostridium: Transmission difficile?
por: Harbarth, Stephan, et al.
Publicado: (2012)

Etymologia: Clostridium difficile
Publicado: (2010)

Clostridium difficile Infection
por: Feuerstadt, Paul
Publicado: (2015)

Asthma Management Guidelines: Updates, Advances, and New Options
por: Navarro, Robert P., et al.
Publicado: (2007)

Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
por: Barnes, Christopher J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7aiccfs0ss318hi9kq47kf7rat